Guerbet Sustainability Profile
Guerbet, a global leader in medical imaging, is headquartered in France and operates extensively across Europe, North America, and Asia. Founded in 1926, the company has established itself as a pioneer in the development of contrast agents and medical imaging solutions, marking significant milestones in innovation and technology throughout its history. Specialising in imaging products for radiology and interventional imaging, Guerbet offers a diverse portfolio that includes contrast media, injectors, and software solutions. Their commitment to quality and safety sets them apart in the industry, ensuring optimal patient care and enhanced diagnostic accuracy. With a strong market position, Guerbet continues to achieve notable advancements, reinforcing its reputation as a trusted partner in the healthcare sector.
DitchCarbon Score
How does Guerbet's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Guerbet's score of 51 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Guerbet's reported carbon emissions
In 2024, Guerbet reported total carbon emissions of approximately 39,081,000 kg CO2e for Scope 1, 12,303,000 kg CO2e for Scope 2 (market-based), and 197,734,000 kg CO2e for Scope 3. This reflects a slight increase in Scope 1 emissions from 38,705,000 kg CO2e in 2023, while Scope 2 emissions decreased from 13,961,000 kg CO2e (market-based) in the previous year. The Scope 3 emissions also rose from 192,436,000 kg CO2e in 2023. Guerbet has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 27.5% by 2032, using 2021 as the base year. Additionally, the company targets a 13.5% reduction in absolute Scope 3 emissions, which encompass emissions from purchased goods and services, fuel and energy activities, upstream transportation and distribution, waste generated in operations, and downstream transportation and distribution, also by 2032. These targets are aligned with the Science Based Targets initiative (SBTi) and are classified as consistent with the reductions required to limit global warming to well below 2°C. The commitments reflect Guerbet's proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 37,539,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 12,241,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 190,570,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Guerbet's Industry?
How Carbon Intensive is Guerbet's Location?
Guerbet's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Guerbet has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
FUJIFILM Holdings Corporation
Merit Medical
Nemoto Kyorindo Co., Ltd.
Frequently Asked Questions
Common questions about Guerbet's sustainability data and climate commitments
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.